PDF(Pubmed)
Abstract：
UNASSIGNED: The incidence of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), after lung cancer resections varies in the literature, and there is limited evidence regarding the optimal duration of thromboprophylaxis. This study aimed at determining the early and long-term occurrence of thromboembolic complications in patients who received in-hospital thromboprophylaxis and underwent resective surgery for lung cancer.
UNASSIGNED: The study included all patients who underwent lung cancer surgery at Tampere University Hospital between 2004 and 2016. Postoperative thromboprophylaxis was administered for the duration of the hospitalization. Data on subsequent episodes of VTE and survival were obtained from national registries. The results were compared to a demographically matched reference population.
UNASSIGNED: The study comprised 435 patients and 4,338 individuals in the reference population. The overall occurrence of VTE in patients and the reference group was 0.3% vs. 0.2% at 90 days (P=0.56), 3.5% vs. 0.7% at 1 year (P<0.001), 9.2% vs. 2.2% at 3 years (P<0.001), and 18.7% and 3.9% at 5 years (P<0.001), respectively. The majority of cases represented PE. The overall mortality at 5 years was 44.4% vs. 11.6% (P<0.001). No associations between patient characteristics and the occurrence of VTE during follow-up were detected.
UNASSIGNED: Patients undergoing lung cancer surgery and who receive in-hospital medical thromboprophylaxis do not seem to be in high risk for symptomatic VTE during the early postoperative period. However, during long-term follow-up the occurrence of symptomatic VTE was significant.
UNASSIGNED: The study included all patients who underwent lung cancer surgery at Tampere University Hospital between 2004 and 2016. Postoperative thromboprophylaxis was administered for the duration of the hospitalization. Data on subsequent episodes of VTE and survival were obtained from national registries. The results were compared to a demographically matched reference population.
UNASSIGNED: The study comprised 435 patients and 4,338 individuals in the reference population. The overall occurrence of VTE in patients and the reference group was 0.3% vs. 0.2% at 90 days (P=0.56), 3.5% vs. 0.7% at 1 year (P<0.001), 9.2% vs. 2.2% at 3 years (P<0.001), and 18.7% and 3.9% at 5 years (P<0.001), respectively. The majority of cases represented PE. The overall mortality at 5 years was 44.4% vs. 11.6% (P<0.001). No associations between patient characteristics and the occurrence of VTE during follow-up were detected.
UNASSIGNED: Patients undergoing lung cancer surgery and who receive in-hospital medical thromboprophylaxis do not seem to be in high risk for symptomatic VTE during the early postoperative period. However, during long-term follow-up the occurrence of symptomatic VTE was significant.
摘要：
■静脉血栓栓塞症（VTE）的发生率，包括深静脉血栓形成（DVT）和肺栓塞（PE），肺癌切除术后的文献各不相同，关于血栓预防的最佳持续时间的证据有限。这项研究旨在确定接受院内血栓预防并接受肺癌切除手术的患者血栓栓塞并发症的早期和长期发生。
■该研究包括2004年至2016年在坦佩雷大学医院接受肺癌手术的所有患者。在住院期间进行术后血栓预防。随后的VTE发作和生存数据来自国家注册局。将结果与人口统计学匹配的参考人群进行比较。
■该研究包括参考人群中的435名患者和4,338名个体。患者和参照组的VTE总发生率为0.3%。90天时为0.2%（P=0.56），3.5%与1年为0.7%(P<0.001)，9.2%与3年为2.2%(P<0.001)，5年分别为18.7%和3.9%(P<0.001)，分别。大多数病例代表PE。5年的总死亡率为44.4%。11.6%(P<0.001)。在随访期间未检测到患者特征与VTE发生之间的关联。
■接受肺癌手术和接受院内药物血栓预防的患者在术后早期似乎没有发生有症状VTE的高风险。然而,在长期随访中,有症状的VTE的发生是显著的.
■该研究包括2004年至2016年在坦佩雷大学医院接受肺癌手术的所有患者。在住院期间进行术后血栓预防。随后的VTE发作和生存数据来自国家注册局。将结果与人口统计学匹配的参考人群进行比较。
■该研究包括参考人群中的435名患者和4,338名个体。患者和参照组的VTE总发生率为0.3%。90天时为0.2%（P=0.56），3.5%与1年为0.7%(P<0.001)，9.2%与3年为2.2%(P<0.001)，5年分别为18.7%和3.9%(P<0.001)，分别。大多数病例代表PE。5年的总死亡率为44.4%。11.6%(P<0.001)。在随访期间未检测到患者特征与VTE发生之间的关联。
■接受肺癌手术和接受院内药物血栓预防的患者在术后早期似乎没有发生有症状VTE的高风险。然而,在长期随访中,有症状的VTE的发生是显著的.
